272 related articles for article (PubMed ID: 15743975)
1. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.
Picard N; Cresteil T; Djebli N; Marquet P
Drug Metab Dispos; 2005 May; 33(5):689-95. PubMed ID: 15743975
[TBL] [Abstract][Full Text] [Related]
2. Novel metabolites of buprenorphine detected in human liver microsomes and human urine.
Chang Y; Moody DE; McCance-Katz EF
Drug Metab Dispos; 2006 Mar; 34(3):440-8. PubMed ID: 16381669
[TBL] [Abstract][Full Text] [Related]
3. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Labroo RB; Paine MF; Thummel KE; Kharasch ED
Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
[TBL] [Abstract][Full Text] [Related]
4. Aromatase is the major enzyme metabolizing buprenorphine in human placenta.
Deshmukh SV; Nanovskaya TN; Ahmed MS
J Pharmacol Exp Ther; 2003 Sep; 306(3):1099-105. PubMed ID: 12808001
[TBL] [Abstract][Full Text] [Related]
5. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.
Moody DE; Slawson MH; Strain EC; Laycock JD; Spanbauer AC; Foltz RL
Anal Biochem; 2002 Jul; 306(1):31-9. PubMed ID: 12069411
[TBL] [Abstract][Full Text] [Related]
6. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharmacol Exp Ther; 2001 Apr; 297(1):326-37. PubMed ID: 11259560
[TBL] [Abstract][Full Text] [Related]
7. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
Usmani KA; Hodgson E; Rose RL
Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry.
Deroussent A; Ré M; Hoellinger H; Cresteil T
J Pharm Biomed Anal; 2010 Jul; 52(3):391-7. PubMed ID: 19804952
[TBL] [Abstract][Full Text] [Related]
10. Oxidative metabolism of lansoprazole by human liver cytochromes P450.
Pichard L; Curi-Pedrosa R; Bonfils C; Jacqz-Aigrain E; Domergue J; Joyeux H; Cosme J; Guengerich FP; Maurel P
Mol Pharmacol; 1995 Feb; 47(2):410-8. PubMed ID: 7870052
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
12. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.
Olesen OV; Linnet K
Br J Clin Pharmacol; 2000 Dec; 50(6):563-71. PubMed ID: 11136295
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes.
Rouguieg K; Picard N; Sauvage FL; Gaulier JM; Marquet P
Drug Metab Dispos; 2010 Jan; 38(1):40-5. PubMed ID: 19841060
[TBL] [Abstract][Full Text] [Related]
14. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.
Sauer C; Peters FT; Schwaninger AE; Meyer MR; Maurer HH
Chem Res Toxicol; 2008 Oct; 21(10):1949-55. PubMed ID: 18778087
[TBL] [Abstract][Full Text] [Related]
15. Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450.
Shou M; Krausz KW; Gonzalez FJ; Gelboin HV
Arch Biochem Biophys; 1996 Apr; 328(1):201-7. PubMed ID: 8638931
[TBL] [Abstract][Full Text] [Related]
16. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism.
Störmer E; von Moltke LL; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):793-801. PubMed ID: 11046120
[TBL] [Abstract][Full Text] [Related]
17. Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H+/K+-ATPase inhibitor KR-60436.
Ji HY; Lee HW; Kim HH; Choi JK; Lee HS
Toxicol Lett; 2005 Jan; 155(1):103-14. PubMed ID: 15585365
[TBL] [Abstract][Full Text] [Related]
18. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
[TBL] [Abstract][Full Text] [Related]
19. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
20. Transplacental transfer and metabolism of buprenorphine in preterm human placenta.
Fokina VM; Patrikeeva SL; Zharikova OL; Nanovskaya TN; Hankins GV; Ahmed MS
Am J Perinatol; 2011 Jan; 28(1):25-32. PubMed ID: 20607647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
